MDMA’s Mark Leahey is confident that the device industry is well positioned to work with the Biden administration and Congress to address the critical issues facing medtech, including healthcare costs, globalization, and the potential legislative agenda. Part two of a two-part interview.
In part one of our conversation, Mark Leahey, President and CEO of the Medical Device Manufacturers Association (MDMA), discussed leadership changes at FDA and CMS, a potential breakdown in regulatory silos, and new COVID-related policies. Here in the second part of our interview, Leahey talks about building on the strong foundation the device industry has laid in recent years to tackle some of the problems facing the global medical device industry. We pick up with a discussion of healthcare costs and pricing transparency, and the shift to increased industry globalization.